Oral valganciclovir as preemptive therapy for cytomegalovirus infection post allogeneic stem cell transplantation

Transplant Infectious Disease

Volumn 9, Issue 2, 2007, Pages 102-107

  Busca, A ^a   De Fabritiis, P ^b   Ghisetti, V ^a   Allice, T ^a   Mirabile, M ^b   Gentile, G ^c   Locatelli, F ^a   Falda, M ^a  

^a MOLINETTE HOSPITAL   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

CMV infection; Preemptive therapy; Stem cell transplantation; Valganciclovir

Indexed keywords

ACICLOVIR; CIDOFOVIR; CYCLOSPORIN A; CYTOMEGALOVIRUS ANTIGEN PP65; ETANERCEPT; FOSCARNET; GANCICLOVIR; INFLIXIMAB; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY; VALGANCICLOVIR;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; DRUG WITHDRAWAL; HUMAN; LUNG ASPERGILLOSIS; MONOTHERAPY; NAUSEA AND VOMITING; NEPHROTOXICITY; NEUTROPENIA; NEUTROPHIL COUNT; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RECURRENT INFECTION; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME; VIRUS DETECTION;

ADMINISTRATION, ORAL; ADULT; AGED; ANTIVIRAL AGENTS; CYTOMEGALOVIRUS INFECTIONS; FEMALE; GANCICLOVIR; GASTROINTESTINAL DISEASES; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; TRANSPLANTATION, HOMOLOGOUS;

EID: 34247643331     PISSN: 13982273     EISSN: 13993062     Source Type: Journal    
DOI: 10.1111/j.1399-3062.2006.00183.x     Document Type: Article

References (20)

1. Boeckh M, Nichols WG, Papanicolaou G, Rubin R, Wingard JR, Zaia J. Cytomegalovirus in hematopoietic stem cell transplant recipients: current status, known challenges, and future strategies. Biol Blood Marrow Transplant 2003 9: 543 558.
2. Pescovitz MD. Oral ganciclovir and pharmacokinetics of valganciclovir in liver transplant recipients. Transpl Infect Dis 1999 1 (Suppl 1): 31 34.
3. Brown F, Banken L, Saywell K, Arum I. Pharmacokinetics of valganciclovir and ganciclovir following multiple oral dosages of valganciclovir in HIV- and CMV-seropositive volunteers. Clin Pharamcokinet 1999 37: 167 176.
4. Drew WL, Ives D, Lalezari JP, et al. Oral ganciclovir as maintenace treatment for cytomegalovirus retinitis in patients with AIDS. N Engl J Med 1995 333: 615 620.
5. Paya C, Humar A, Dominguez E, et al. Efficacy and safety of valganciclovir vs oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2004 4: 611 620.
6. Winston DJ, Ratanatharathorn V, Baden L, et al. Pharmacokinetics of ganciclovir following oral valganciclovir in allogeneic hematopoietic stem-cell transplant patients with stable graft-versus-host disease of the gastrointestinal tract. American Society of Hematology 46th annual meeting, San Diego, CA, December 2004, Abstract 2223.
7. Eisele H. Valganciclovir for CMV pre-emptive therapy early after SCT. 20th Annual Meeting of the European Group for Blood and Marrow Transplantation, Barcelona, Spain, 2004.
8. ClinicalTrials.gov. Valganciclovir to prevent cytomegalovirus infection in patients following donor stem cell transplantation.
9. Ljungman P, Griffiths P, Paya C. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin infect Dis 2002 34: 1094 1097.
10. Valcyte (Product Information). Roche Laboratories: Nutley, NJ. 2001.
11. Pescovitz MD, Babkin J, Merion RM, et al. Valganciclovir results in improved oral absorption of ganciclovir in liver transplant recipients. Antimicrob Agents Chemother 2000 44: 2811 2815.
12. Abete JF, Martin-Davila P, Moreno S, Quijano Y, de Vincente E, Pou L. Pharmacokinetics of oral valganciclovir and intravenous ganciclovir administered to prevent cytomegalovirus disease in an adult patient receiving small-intestine transplantation. Antimicrob Agents Chemother 2004 48: 2782 2783.
13. Ciancio G, Burke GW, Mattiazzi A, et al. Cytomegalovirus prophylaxis with valganciclovir in kidney, pancreas-kidney, and pancreas transplantation. Clin Transplant 2004 18: 402 406.
14. Humar A, Siegal D, Moussa G, Kumar D. A prospective assessment of valganciclovir for the treatment of cytomegalovirus infection and disease in transplant recipients. J Infect Dis 2005 192: 1154 1157.
15. Paya C, Humar A, Dominguez ED, et al. Efficacy and safety of valganciclovir vs oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2004 4: 611 620.
16. Singh N, Wannstedt C, Keyes L, et al. Efficacy of valganciclovir administered as preemptive therapy for cytomegalovirus disease in liver transplant recipients: impact on viral load and late-onset cytomegalovirus disease. Transplantation 2005 79: 85 90.
17. Gonzales H, Vernant JP, Caumes E. Successful oral ganciclovir treatment of cytomegalovirus infection during Campath-1H therapy. Leukemia 2005 19: 478.
18. Leather HL, Meyer CL, Wingard JR. Oral valganciclovir for preemptive therapy of cytomegalovirus antigenemia in hematopoietic stem cell transplant recipients. Biol Blood Marrow Transplant 2003 9: 132 (abstract 238).
19. Antin JH. Long-term care after hematopoietic-cell transplantation in adults. N Engl J Med 2002 347: 36 42.
20. Einsele H, Reusser P, Bornhauser M, et al. Oral valganciclovir leads to higher exposure to ganciclovir than intravenous ganciclovir in patients following allogeneic stem cell transplantation. Blood 2006 107: 3002 3008. Epub 2005 Dec 13.